Multicenter clinical trial of leuprolide acetate depot (Luphere depot 3.75 mg) for efficacy and safety in girls with central precocious puberty
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김유진 | - |
dc.contributor.author | 이해상 | - |
dc.contributor.author | 이영준 | - |
dc.contributor.author | 임중섭 | - |
dc.contributor.author | 김세영 | - |
dc.contributor.author | 김은영 | - |
dc.contributor.author | 진동규 | - |
dc.contributor.author | Il Tae Hwang | - |
dc.contributor.author | 황진순 | - |
dc.date.accessioned | 2021-09-06T07:09:00Z | - |
dc.date.available | 2021-09-06T07:09:00Z | - |
dc.date.created | 2021-06-17 | - |
dc.date.issued | 2013 | - |
dc.identifier.issn | 1226-2242 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/104893 | - |
dc.description.abstract | Purpose: We evaluated the efficacy, safety and psychological aspect of monthly administrations of the gonadotropin-releasing hormone agonists (GnRHa), leuprolide acetate depot (Luphere depot 3.75 mg), in patients with precocious puberty. Methods: A total of 54 girls with central precocious puberty were administered with leuprolide acetate (Luphere depot 3.75 mg) every four weeks over 24 weeks. We evaluated the percentage of children exhibiting a suppressed luteinizing hormone (LH)response to GnRH (LH peak≤3 IU/L), peak LH/follicle stimulating hormone (FSH) ratio of GnRH stimulation test less than 1, change in bone age/chronologic age ratio, change in the Tanner stage and change in eating habit and psychological aspect. Results: (1) The percentage of children exhibiting a suppressed LH response to GnRH,defined as an LH peak≤3 IU/L at 24 weeks was 96.3 % (52/54). (2) The percentage of children exhibiting peak LH/FSH ratio<1 at 24 weeks of the study was 94.4 % (51/54). (3) The ratio of bone age and chronological age significantly declined from 1.27±0.07to 1.24±0.01 after the 6 months of the study. (4) The mean Tanner stage manifested a significant change 2.3±0.48 at baseline, down to 1.70±0.61 at 24 weeks. (5) Based on the questionnaires, the score for eating habits showed a significant change from the baseline 34.0±6.8 to 31.3±6.8. (6) The psychological assessment did not exhibit a significant difference except with scores for sociability, problem behavior total score and other problems. Conclusion: The leuprolide 3.75 mg (Luphere depot) is useful and safety for treating children with central precocious puberty. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | 대한소아내분비학회 | - |
dc.title | Multicenter clinical trial of leuprolide acetate depot (Luphere depot 3.75 mg) for efficacy and safety in girls with central precocious puberty | - |
dc.title.alternative | Multicenter clinical trial of leuprolide acetate depot (Luphere depot 3.75 mg) for efficacy and safety in girls with central precocious puberty | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | 이영준 | - |
dc.identifier.bibliographicCitation | Annals of Pediatirc Endocrinology & Metabolism, v.18, no.4, pp.173 - 178 | - |
dc.relation.isPartOf | Annals of Pediatirc Endocrinology & Metabolism | - |
dc.citation.title | Annals of Pediatirc Endocrinology & Metabolism | - |
dc.citation.volume | 18 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 173 | - |
dc.citation.endPage | 178 | - |
dc.type.rims | ART | - |
dc.identifier.kciid | ART001831774 | - |
dc.description.journalClass | 2 | - |
dc.description.journalRegisteredClass | kci | - |
dc.subject.keywordAuthor | Leuprolide acetate | - |
dc.subject.keywordAuthor | Central precocious puberty | - |
dc.subject.keywordAuthor | Treatment outcome | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.